In endometrial cancer, reduced METTL3 expression leads to a decrease in m6A modification on PHLPP2 mRNA, resulting in attenuated YTHDF1-mediated translation of PHLPP2, which in turn caused de-repression of the AKT pathway and promotes tumor progression [66]. Here, PHLPP2 is linked to endometrial cancer.